• 6 min read
• Published on 28 August 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
Let’s be honest, nobody enjoys a needle. It’s a primal, almost childish aversion, but a powerful one nonetheless. For years, this simple fact has been a frustrating barrier for some of the most effective weight-loss drugs on the planet. The likes of Ozempic and Wegovy have worked wonders, but they’ve always come with the sting of a weekly injection. To me, that always seemed like a commercial vulnerability just waiting to be exploited.
Now, it seems the day of reckoning might be upon us. Eli Lilly, a titan of the pharmaceutical world, has reported rather promising results for its oral drug, orforglipron. Suddenly, the prospect of achieving similar results with a simple pill is no longer a distant dream. This isn't just a tweak or a minor upgrade, it’s a potential earthquake set to rattle a multi-billion pound industry.
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
If I were a senior executive at Novo Nordisk, the Danish firm behind Ozempic and Wegovy, I might be feeling a tad queasy. They have, for years, been the undisputed kings of the GLP-1 market. They built an empire on the back of injectable treatments, and a mighty profitable one at that. But dominance built on a delivery method that people actively dislike is a fragile sort of power.
Eli Lilly’s move puts Novo Nordisk in a classic bind. Do they rush their own oral version to market and risk cannibalising their own cash cows? Or do they hold firm and hope the convenience of a pill isn't enough to lure patients away? It’s a fascinating strategic dilemma. History teaches us that when a more convenient technology comes along, it almost always wins. Think of streaming services versus video rental shops. The outcome is rarely in doubt, it’s just a matter of when.
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
Of course, this isn't just a two-horse race. The scent of enormous profits has attracted a whole host of smaller, nimbler biotech firms. Companies like Structure Therapeutics are entirely focused on creating oral alternatives, unburdened by a legacy of injectable products they need to protect. They are the speedboats zipping around the oil tankers, able to pivot and innovate without the corporate inertia that can plague the giants.
From an investor’s perspective, this creates a rather tantalising, if perilous, landscape. Do you back the established behemoth, Eli Lilly, which seems to have a head start? Or do you place a bet on a smaller, more speculative biotech that could, if its trials succeed, deliver explosive returns? There is no simple answer, and the risks are as significant as the potential rewards. To me, this whole saga looks like a classic case of disruption, a theme we've explored in our Beyond The Needle: The Oral GLP-1 Revolution basket.
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
Ultimately, the biggest winner in all this will likely be the patient. Removing the needle barrier could dramatically expand access to these life-changing treatments for obesity and diabetes. A simple pill is easier to take, easier to stick with, and frankly, far less intimidating. This convenience factor alone could unlock a market of millions who were previously put off by the prospect of regular injections.
For investors, the next few years will be a volatile but compelling watch. Clinical trial data will be scrutinised, regulatory decisions will move share prices, and the competitive jostling will be intense. Picking the ultimate winner today is a fool’s errand. The key will be to watch how these companies navigate the immense technical and commercial hurdles ahead. The firm that masters the science, scales production, and gets its pricing right could well dominate the next decade of metabolic medicine.
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
View the full Basket:Beyond The Needle: The Oral GLP-1 Revolution
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article